Recent years have seen an explosion of emerging data technologies in the biotech sector. Many of these address long-standing challenges in the industry, offering the potential to reduce the time and cost of drug discovery, and to target beyond what was previously possible. But new opportunities bring new challenges. Ethical harnessing of data, access to and governance of data, skills and interoperability all provide significant hurdles.
Life science companies, keen to tap into computational power and access the potential of vast datasets, will need different capabilities to take the potential forward. Equally, technology-based organisations need to get to grips with the world of biotech in order to understand where they can add the most value.